Plexxikon Inc. Announces Data Presentations of Oncology Pipeline, Including Phase 3 Vemurafenib Data, at American Society of Clinical Oncology 2011 Annual Meeting
5/18/2011 9:52:57 AM
BERKELEY, Calif.--(BUSINESS WIRE)--Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced that data related to vemurafenib and PLX3397, two promising oncology drugs in its pipeline, will be presented in ten separate presentations at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting taking place June 3 through June 7, 2011 in Chicago, Illinois.
comments powered by